Journal article
J. Chora, M. Bourbon
Current opinion in lipidology, vol. 32(2), 2021, pp. 96-102
Current opinion in lipidology, vol. 32(2), 2021, pp. 96-102
Semantic Scholar
DOI
PubMed
Cite
Cite
APA
Click to copy
Chora, J., & Bourbon, M. (2021). Pharmacogenomics of statins and familial hypercholesterolemia. Current Opinion in Lipidology, 32(2), 96–102. https://doi.org/10.1097/MOL.0000000000000746
Chicago/Turabian
Click to copy
Chora, J., and M. Bourbon. “Pharmacogenomics of Statins and Familial Hypercholesterolemia.” Current opinion in lipidology 32, no. 2 (2021): 96–102.
MLA
Click to copy
Chora, J., and M. Bourbon. “Pharmacogenomics of Statins and Familial Hypercholesterolemia.” Current Opinion in Lipidology, vol. 32, no. 2, 2021, pp. 96–102, doi:10.1097/MOL.0000000000000746.
BibTeX Click to copy
@article{j2021a,
title = {Pharmacogenomics of statins and familial hypercholesterolemia},
year = {2021},
issue = {2},
journal = {Current opinion in lipidology},
pages = {96-102},
volume = {32},
doi = {10.1097/MOL.0000000000000746},
author = {Chora, J. and Bourbon, M.}
}
Abstract
Purpose of review To collect evidence on statin pharmacogenomics, and review what is known in this field for familial hypercholesterolemia (FH) patients. Recent findings There are well-known associations between specific single nucleotide polymorphisms involved in statin transport and metabolism and either adverse effects or altered lipid-lowering efficacy. However, the applicability of this knowledge is uncertain, especially in high-risk populations. There are alternative approaches to study plasma concentrations of statins and new insights on why some association studies fail to be replicated. Summary Statin therapy recommendations are not always followed in primary and secondary prevention and, even when followed, patients often fail to reach therapeutic target values. Considering the stringent 2019 European Atherosclerosis Society and European Society of Cardiology recommended target lipid levels, as well as the persistently high cost for alternative lipid-lowering therapies such as PCSK9 inhibitors, the variability in low-density lipoprotein cholesterol reductions on statin therapy is still an important factor that needs to be addressed to ensure better cardiovascular disease risk management, especially for FH patients, who have not been well studied historically in this context.
